AMI Asset Management Corp Has $2.24 Million Holdings in SpringWorks Therapeutics (NASDAQ:SWTX)

AMI Asset Management Corp raised its holdings in SpringWorks Therapeutics (NASDAQ:SWTX - Free Report) by 27.3% in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 50,640 shares of the company's stock after purchasing an additional 10,849 shares during the quarter. AMI Asset Management Corp owned approximately 0.07% of SpringWorks Therapeutics worth $2,235,000 as of its most recent SEC filing.

Other institutional investors have also recently bought and sold shares of the company. Huntington National Bank raised its position in SpringWorks Therapeutics by 38.2% in the 4th quarter. Huntington National Bank now owns 694 shares of the company's stock valued at $25,000 after purchasing an additional 192 shares during the last quarter. AlphaQuest LLC raised its position in SpringWorks Therapeutics by 70.2% in the 4th quarter. AlphaQuest LLC now owns 1,004 shares of the company's stock valued at $36,000 after purchasing an additional 414 shares during the last quarter. Venturi Wealth Management LLC bought a new position in SpringWorks Therapeutics in the 4th quarter valued at $45,000. State of Wyoming raised its position in SpringWorks Therapeutics by 39.5% in the 4th quarter. State of Wyoming now owns 1,530 shares of the company's stock valued at $55,000 after purchasing an additional 433 shares during the last quarter. Finally, GF Fund Management CO. LTD. bought a new position in SpringWorks Therapeutics in the 4th quarter valued at $56,000.

SpringWorks Therapeutics Price Performance

Shares of NASDAQ SWTX traded down $0.01 during midday trading on Friday, hitting $46.98. The stock had a trading volume of 8,230,719 shares, compared to its average volume of 2,526,632. SpringWorks Therapeutics has a fifty-two week low of $28.21 and a fifty-two week high of $62.00. The company's 50-day simple moving average is $46.05 and its 200 day simple moving average is $44.22. The firm has a market cap of $3.54 billion, a P/E ratio of -13.78 and a beta of 0.70.

SpringWorks Therapeutics (NASDAQ:SWTX - Get Free Report) last announced its quarterly earnings data on Friday, May 9th. The company reported ($1.11) EPS for the quarter, missing analysts' consensus estimates of ($0.81) by ($0.30). SpringWorks Therapeutics had a negative return on equity of 51.10% and a negative net margin of 115.60%. The company had revenue of $49.09 million for the quarter, compared to analyst estimates of $64.19 million. Equities analysts expect that SpringWorks Therapeutics will post -2.05 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts have issued reports on the company. Barclays reiterated an "equal weight" rating and issued a $47.00 price objective (down previously from $63.00) on shares of SpringWorks Therapeutics in a research report on Monday, April 28th. Wedbush reissued a "neutral" rating and issued a $47.00 target price (down from $81.00) on shares of SpringWorks Therapeutics in a research note on Monday, April 28th. TD Cowen reissued a "hold" rating and issued a $47.00 target price (down from $66.00) on shares of SpringWorks Therapeutics in a research note on Tuesday, April 29th. Evercore ISI cut SpringWorks Therapeutics from a "strong-buy" rating to a "hold" rating in a research note on Monday, April 28th. Finally, HC Wainwright reissued a "neutral" rating and issued a $47.00 target price (down from $74.00) on shares of SpringWorks Therapeutics in a research note on Wednesday, April 30th. Seven analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of "Hold" and a consensus target price of $52.57.

SpringWorks Therapeutics Profile

SpringWorks Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer.